Stockwatch: Courage Under Fire
This article was originally published in Scrip
Executive Summary
One of the most frightening experiences I had as an infantry soldier was to come under, albeit simulated, mortar fire. Sitting in a damp ditch at night whilst the enemy threw what would have been high explosive and shrapnel at me gave me nightmares for weeks afterwards. In a very metaphorical sense, this is what the stock market for life science stocks feels like at the moment.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.